UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Promising Findings in Myeloproliferative Neoplasms and AL Amyloidosis

Healthbook TIMES. Oncology Hematology, 2022-09 (13)

Axel Rüfer

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium

PloS one, 2022-04, Vol.17 (4), p.e0267342-e0267342

2022

Link zum Volltext

Verfügbarkeit prüfen

Swiss Amyloidosis Network (SAN): Objectives and Challenges

Healthbook TIMES. Oncology Hematology, 2023-12, Vol.18 (18)

2023

Link zum Volltext

Verfügbarkeit prüfen

Management of transthyretin amyloidosis

Swiss medical weekly, 2021-10, Vol.151, p.w30053

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of a JAK2 FERM Domain Variant Associated With Hereditary Thrombocytosis

HemaSphere, 2021-08, Vol.5 (8), p.e626-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Burden of immune thrombocytopenia ( ITP ): Special considerations for refractory ITP

British journal of haematology, 2023-10, Vol.203 (1), p.79-85

2023

Link zum Volltext

Verfügbarkeit prüfen

Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload

Swiss medical weekly, 2017-11, Vol.147, p.w14550

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

HemaSphere, 2023-05, Vol.7 (5), p.e882-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Reference values for oral iron absorption of bivalent iron in healthy volunteers

Swiss medical weekly, 2015-01, Vol.145, p.w14063

2015

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulation with romiplostim as a second‐line strategy in primary immune thrombocytopenia: The iROM study

British journal of haematology, 2023-10, Vol.203 (1), p.119-130

2023

Link zum Volltext

Verfügbarkeit prüfen

Systemic AL Amyloidosis and Precision Medicine

Healthbook TIMES. Oncology Hematology, 2021-06, Vol.2 (8)

2021

Link zum Volltext

Verfügbarkeit prüfen

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Blood, 2018-11, Vol.132 (19), p.2097-2100

2018

Link zum Volltext

Verfügbarkeit prüfen

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Leukemia, 2023-03, Vol.37 (3), p.699-701

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulation with Romiplostim in Young Adult Primary Immune Thrombocytopenia (ITP) As Second-Line Strategy (iROM-study)

Blood, 2021-11, Vol.138 (Supplement 1), p.3149-3149

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium

PloS one, 2022-01, Vol.17 (4), p.e0267342

2022

Link zum Volltext

Verfügbarkeit prüfen

Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries

Cancer epidemiology, 2019-04, Vol.59, p.51-57

2019

Link zum Volltext

Verfügbarkeit prüfen

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Blood advances, 2023-05, Vol.7 (9), p.1713-1724

2023

Link zum Volltext

Verfügbarkeit prüfen

The spleen in non-malignant haematological disorders

Therapeutische Umschau, 2013-03, Vol.70 (3), p.157

2013

Link zum Volltext

Verfügbarkeit prüfen

Hereditary hyperferritinemia‐cataract syndrome (HHCS) presenting with iron deficiency anemia associated with a new mutation in the iron responsive element of the L ferritin gene in a swiss family

European journal of haematology, 2011-09, Vol.87 (3), p.274-278

2011

Link zum Volltext

Verfügbarkeit prüfen

Hereditary hyperferritinemia-cataract syndrome (HHCS) presenting with iron deficiency anemia associated with a new mutation in the iron responsive element of the L ferritin gene in a swiss family: HHCS presenting with iron deficiency anemia

European journal of haematology, 2011-09, Vol.87 (3), p.274-278

2011

Link zum Volltext

Verfügbarkeit prüfen

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature

Swiss medical weekly, 2007-09, Vol.137 (37-38), p.518

2007

Link zum Volltext

Verfügbarkeit prüfen

P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study)

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S165-S165

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of a JAK2 FERM Domain Variant Associated With Hereditary Thrombocytosis

HemaSphere, 2021, Vol.5 (8), p.e626-e626

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Swiss Medical Weekly
(4)
Blood
(3)
Healthbook Times. Oncology Hematology
(3)
Hemasphere
(3)
Age And Ageing
(2)
British Journal Of Haematology
(2)
European Journal Of Haematology
(2)
Plos One
(2)
Blood Advances
(1)
Cancer Epidemiology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Promising Findings in Myeloproliferative Neoplasms and AL Amyloidosis

Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium

Swiss Amyloidosis Network (SAN): Objectives and Challenges

Management of transthyretin amyloidosis

Identification of a JAK2 FERM Domain Variant Associated With Hereditary Thrombocytosis

Burden of immune thrombocytopenia ( ITP ): Special considerations for refractory ITP

Real‐world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

Reference values for oral iron absorption of bivalent iron in healthy volunteers

Immunomodulation with romiplostim as a second‐line strategy in primary immune thrombocytopenia: The iROM study

Systemic AL Amyloidosis and Precision Medicine

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Immunomodulation with Romiplostim in Young Adult Primary Immune Thrombocytopenia (ITP) As Second-Line Strategy (iROM-study)

Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium

Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

The spleen in non-malignant haematological disorders

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Hereditary hyperferritinemia‐cataract syndrome (HHCS) presenting with iron deficiency anemia associated with a new mutation in the iron responsive element of the L ferritin gene in a swiss family

Hereditary hyperferritinemia-cataract syndrome (HHCS) presenting with iron deficiency anemia associated with a new mutation in the iron responsive element of the L ferritin gene in a swiss family: HHCS presenting with iron deficiency anemia

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature

P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study)

Identification of a JAK2 FERM Domain Variant Associated With Hereditary Thrombocytosis

Suchergebnisse filtern